# A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)

Study · id `cardio:ct-nct06450366` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06450366](<https://clinicaltrials.gov/study/NCT06450366>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06450366

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 301 participants.

## Technical summary

Registry record NCT06450366. Randomized; triple masking; primary purpose treatment. Start 2024-07-08 (actual); primary completion 2025-02-14 (actual). Results posted on 2026-03-27.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 301 participants (enrolled count; ClinicalTrials.gov record NCT06450366, source copy `cardio:ctgov-nct06450366-2026-03-27`, retrieved 2026-10-31)
- Started: 2024-07-08 (actual) (ClinicalTrials.gov record NCT06450366, source copy `cardio:ctgov-nct06450366-2026-03-27`, retrieved 2026-10-31)
- Primary completion: 2025-02-14 (actual) (ClinicalTrials.gov record NCT06450366, source copy `cardio:ctgov-nct06450366-2026-03-27`, retrieved 2026-10-31)
- Completion: 2025-03-28 (actual) (ClinicalTrials.gov record NCT06450366, source copy `cardio:ctgov-nct06450366-2026-03-27`, retrieved 2026-10-31)
- Results first posted: 2026-03-27 (ClinicalTrials.gov record NCT06450366, source copy `cardio:ctgov-nct06450366-2026-03-27`, retrieved 2026-10-31)
- Countries: United States; Argentina; Canada; France; Israel; Spain; Taiwan; United Kingdom (ClinicalTrials.gov record NCT06450366, source copy `cardio:ctgov-nct06450366-2026-03-27`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06450366-2026-03-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)
- Condition: Hypercholesterolemia
- Intervention (Drug): Enlicitide
- Intervention (Drug): Ezetimibe
- Intervention (Drug): Bempedoic Acid
- Intervention (Other): Placebo for Enlicitide
- Intervention (Other): Placebo for Ezetimibe
- Intervention (Other): Placebo for Bempedoic Acid
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Ezetimibe (`cardio:ezetimibe`)
- Registry intervention name matches this record: Bempedoic acid (`cardio:bempedoic-acid`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial (`cardio:pubmed-42017875`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: d6fc619948e0036942accdcb524a0b7cceb8a59531ae462c7f26c1591e7b7f26
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
